APGE

NEUTRALM&A

Apogee Therapeutics, Inc.

2026-08-31

Price

$135.08

+0.08%

This is the 2026-08-31 snapshot — the signals and analysis for APGE as of this single trading day.

View full APGE research hub →

Score13.5Top Tier

Signals6/8 DNA2/13 Act · 0/4 Risk

SentimentNEUTRALScore: 0

Volume1.4xvs 20d avg

Analysis

The stock is trading as a pure merger arbitrage play because AbbVie has agreed to acquire Apogee Therapeutics for $135.11 per share in cash. This M&A catalyst perfectly explains the 'Quiet Storm' and 'Steady Climb' technical signals, as well as the ultra-low 1.4% realized volatility, as the price is firmly pinned just 3 cents below the buyout price. While the broader market is in a Geopolitical Risk-On regime with strong credit liquidity, APGE's price action and conviction level are entirely idiosyncratic, driven solely by the mechanics of the pending Q3 2026 deal closure rather than macroeconomic forces.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSMARKET LEADERPERFECT STACKQUIET ACCUMULATIONINSIDE OUT

Key Takeaways

Actionable Thesis: APGE is a definitive merger arbitrage play trading at $135.08, leaving a negligible 3-cent upside to the $135.11 cash deal price.
Key Risk: Regulatory (FTC) pushback or shareholder vote failure are the only material risks that could break the deal and cause a severe downside repricing.
What to Watch: Monitor antitrust regulatory filings and the definitive proxy for the upcoming shareholder vote to finalize the Q3 2026 closing.

← Back to 2026-08-31 View Full APGE History →Yahoo Finance &nearr;